Vanguard Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vanguard Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$128M	Buy	3,112,937 +49,802	+2%	+$2M	﹤0.01%	1758
2025 Q3	$119M	Sell	3,063,135 -68,467	-2%	-$2.22M	﹤0.01%	1779
2025 Q2	$86.7M	Sell	3,131,602 -227,499	-7%	-$5.79M	﹤0.01%	1888
2025 Q1	$74.6M	Buy	3,359,101 +151,604	+5%	+$3.12M	﹤0.01%	1923
2024 Q4	$63.4M	Sell	3,207,497 -90,759	-3%	-$2.07M	﹤0.01%	2064
2024 Q3	$82.4M	Buy	+3,298,256	New	+$80.3M	﹤0.01%	1964
2024 Q2	–	Sell	-2,981,894	Closed	-$58.8M	–	4425
2024 Q1	$58.8M	Buy	2,981,894 +16,595	+0.6%	+$324K	﹤0.01%	2089
2023 Q4	$52M	Buy	2,965,299 +6,342	+0.2%	+$104K	﹤0.01%	2176
2023 Q3	$51.4M	Sell	2,958,957 -128,255	-4%	-$2.16M	﹤0.01%	2126
2023 Q2	$43.5M	Sell	3,087,212 -173,411	-5%	-$2.32M	﹤0.01%	2246
2023 Q1	$35.1M	Buy	3,260,623 +33,732	+1%	+$444K	﹤0.01%	2342
2022 Q4	$48.3M	Buy	3,226,891 +147,699	+5%	+$2.15M	﹤0.01%	2203
2022 Q3	$39.5M	Buy	3,079,192 +151,211	+5%	+$1.72M	﹤0.01%	2295
2022 Q2	$28.4M	Sell	2,927,981 -78,669	-3%	-$734K	﹤0.01%	2470
2022 Q1	$29.9M	Buy	3,006,650 +115,942	+4%	+$1.23M	﹤0.01%	2566
2021 Q4	$34M	Buy	2,890,708 +228,082	+9%	+$2.8M	﹤0.01%	2559
2021 Q3	$30.3M	Sell	2,662,626 -1,697	-0.1%	-$22.1K	﹤0.01%	2638
2021 Q2	$37.1M	Sell	2,664,323 -138,724	-5%	-$2.11M	﹤0.01%	2525
2021 Q1	$51.9M	Buy	2,803,047 +266,626	+11%	+$5.45M	﹤0.01%	2294
2020 Q4	$44.8M	Buy	2,536,421 +164,137	+7%	+$2.88M	﹤0.01%	2260
2020 Q3	$36.3M	Buy	2,372,284 +657,342	+38%	+$12.3M	﹤0.01%	2171
2020 Q2	$43.7M	Buy	1,714,942 +514,431	+43%	+$10.7M	﹤0.01%	2069
2020 Q1	$18.6M	Sell	1,200,511 -942	-0.1%	-$14.7K	﹤0.01%	2327
2019 Q4	$13.3M	Buy	1,201,453 +34,942	+3%	+$304K	﹤0.01%	2722
2019 Q3	$9.93M	Sell	1,166,511 -76,851	-6%	-$849K	﹤0.01%	2819
2019 Q2	$16.8M	Sell	1,243,362 -2,862	-0.2%	-$44.4K	﹤0.01%	2599
2019 Q1	$22.5M	Buy	1,246,224 +337,951	+37%	+$6.53M	﹤0.01%	2450
2018 Q4	$25.5M	Buy	908,273 +352,282	+63%	+$7.35M	﹤0.01%	2336
2018 Q3	$14.2M	Buy	555,991 +405,991	+271%	+$7.89M	﹤0.01%	2750
2018 Q2	$2.6M	Buy	+150,000	New	+$2.71M	﹤0.01%	3418

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Vanguard Group's KNSA Position: Q4 2025 in Review

Vanguard Group increased its Kiniksa Pharmaceuticals (KNSA) stake by 1.6% in Q4 2025, buying an estimated $2M and bringing the position to 3,112,937 shares worth $128M. The position accounts for ﹤0.01% of the portfolio, ranked #1758.

Vanguard Group first reported a position in KNSA in Q2 2018 and has held it in 30 quarters since. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

Vanguard Group held 3,112,937 shares of Kiniksa Pharmaceuticals worth $128M as of Q4 2025.
Vanguard Group bought 49,802 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $2M.
Kiniksa Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1758 holding.
Vanguard Group first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.